Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
84.90
+1.14 (+1.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
56
57
Next >
Biden Says US Ready To Share COVID-19 Vaccine Related Technology
May 13, 2022
Via
Benzinga
White House Says Currently No Plans To Share COVID-19 Shots With North Korea Battling Outbreak
May 13, 2022
The Biden administration says it currently has no plans to share COVID-19 vaccines with North Korea, Reuters reported citing White House press secretary Jen Psaki. However, it supported providing aid...
Via
Benzinga
Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco
May 11, 2022
Via
Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
May 11, 2022
Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV).
Via
Benzinga
PR Agency Tells Blue-Chip Clients Like AT&T, Coca-Cola, Netflix And More To Avoid Media Inquiries On Abortion Debate
May 06, 2022
A prominent public relations agency is warning its publicly traded clients to avoid making any comments on the Roe v.
Via
Benzinga
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
May 05, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
US Study Shows Omicron As Severe As Previous COVID Variants: Reuters
May 05, 2022
Via
Benzinga
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
May 05, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
May 05, 2022
From
AstraZeneca
Via
Business Wire
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
May 05, 2022
From
AstraZeneca
Via
Business Wire
FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review
May 04, 2022
The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care...
Via
Benzinga
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
May 04, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca's Imfinzi/Chemo Combo Goes Under Priority FDA Review For Bile Duct Cancer
May 04, 2022
Via
Benzinga
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
May 04, 2022
Via
Viz Release
Exposures
COVID-19
Product Safety
Fourth COVID-19 Shot? See Why Medical Professionals Are Skeptical
May 02, 2022
Medical professionals are undecided on whether a fourth dose of the Covid-19 vaccine would benefit the wider population, as countries are beginning to offer the fourth dose to vulnerable groups.
Via
Benzinga
4 Healthcare Funds With "Double Discounts"
April 30, 2022
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look...
Via
Talk Markets
Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales
April 29, 2022
Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.
Via
Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
April 29, 2022
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings.
Via
Investor's Business Daily
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
AstraZeneca: Q1 Earnings Insights
April 29, 2022
AstraZeneca (NASDAQ:AZN) reported its Q1 earnings results on Friday, April 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AstraZeneca reported an EPS of...
Via
Benzinga
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
April 29, 2022
Via
Benzinga
A Peek Into The Markets: US Stock Futures Down; Apple Tops Q2 Views
April 29, 2022
Pre-open movers
Via
Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For April 29, 2022
April 29, 2022
Companies Reporting Before The Bell • Weyerhaeuser (NYSE:WY) is projected to report quarterly earnings at $1.19 per share on revenue of $2.93 billion.
Via
Benzinga
Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg
April 28, 2022
At least six U.S. states are reporting confirmed or suspected cases of an unexplained, severe liver disorder in children. Health officials in New York state and Wisconsin said they’re investigating...
Via
Benzinga
ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
April 28, 2022
From
AstraZeneca
Via
Business Wire
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
April 27, 2022
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
56
57
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.